BioLife Solutions Inc (NASDAQ:BLFS) VP Sells $44,850.00 in Stock

Share on StockTwits

BioLife Solutions Inc (NASDAQ:BLFS) VP James Mathers sold 2,500 shares of the business’s stock in a transaction on Tuesday, July 9th. The stock was sold at an average price of $17.94, for a total transaction of $44,850.00. Following the sale, the vice president now directly owns 19,884 shares in the company, valued at approximately $356,718.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

James Mathers also recently made the following trade(s):

  • On Thursday, July 11th, James Mathers sold 2,500 shares of BioLife Solutions stock. The stock was sold at an average price of $17.15, for a total transaction of $42,875.00.

NASDAQ BLFS opened at $16.93 on Friday. The company has a market capitalization of $318.27 million, a PE ratio of 120.93 and a beta of 1.31. The business’s fifty day moving average is $17.22. The company has a current ratio of 14.50, a quick ratio of 12.99 and a debt-to-equity ratio of 0.02. BioLife Solutions Inc has a fifty-two week low of $9.15 and a fifty-two week high of $26.35.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, May 9th. The medical equipment provider reported $0.03 EPS for the quarter, hitting analysts’ consensus estimates of $0.03. The company had revenue of $5.77 million for the quarter, compared to analyst estimates of $5.67 million. BioLife Solutions had a net margin of 17.01% and a return on equity of 10.32%. As a group, analysts expect that BioLife Solutions Inc will post 0.12 EPS for the current year.

A number of research firms have weighed in on BLFS. Zacks Investment Research cut shares of ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday. BidaskClub cut shares of Weyco Group from a “sell” rating to a “strong sell” rating in a research note on Saturday. Maxim Group set a $24.00 target price on shares of BioLife Solutions and gave the stock a “buy” rating in a research note on Wednesday, May 22nd. ValuEngine raised shares of XCel Brands from a “sell” rating to a “hold” rating in a research note on Tuesday, July 9th. Finally, Northland Securities boosted their target price on shares of Paycom Software from $215.00 to $275.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 9th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $17.80.

Several large investors have recently modified their holdings of the company. Bank of New York Mellon Corp grew its holdings in BioLife Solutions by 36.1% in the fourth quarter. Bank of New York Mellon Corp now owns 64,930 shares of the medical equipment provider’s stock valued at $781,000 after purchasing an additional 17,209 shares during the last quarter. GSA Capital Partners LLP boosted its stake in shares of BioLife Solutions by 21.1% during the fourth quarter. GSA Capital Partners LLP now owns 13,800 shares of the medical equipment provider’s stock valued at $166,000 after acquiring an additional 2,400 shares during the last quarter. Northern Trust Corp boosted its stake in shares of BioLife Solutions by 19.2% during the fourth quarter. Northern Trust Corp now owns 49,729 shares of the medical equipment provider’s stock valued at $598,000 after acquiring an additional 8,003 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of BioLife Solutions by 34.1% during the fourth quarter. Geode Capital Management LLC now owns 83,588 shares of the medical equipment provider’s stock valued at $1,005,000 after acquiring an additional 21,267 shares during the last quarter. Finally, Barclays PLC boosted its stake in shares of BioLife Solutions by 18,125.0% during the fourth quarter. Barclays PLC now owns 72,900 shares of the medical equipment provider’s stock valued at $877,000 after acquiring an additional 72,500 shares during the last quarter. Institutional investors own 45.76% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Featured Article: What is the price-sales ratio?

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Barry Zwarenstein Sells 7,663 Shares of Five9 Inc  Stock
Barry Zwarenstein Sells 7,663 Shares of Five9 Inc Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc  Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc Stock
Insider Selling: Neogen Co.  Director Sells 5,000 Shares of Stock
Insider Selling: Neogen Co. Director Sells 5,000 Shares of Stock
Neogen Co.  Director Sells $314,650.00 in Stock
Neogen Co. Director Sells $314,650.00 in Stock
Insider Selling: Airgain Inc  CEO Sells 22,464 Shares of Stock
Insider Selling: Airgain Inc CEO Sells 22,464 Shares of Stock
Insider Selling: Bottomline Technologies  Insider Sells 9,925 Shares of Stock
Insider Selling: Bottomline Technologies Insider Sells 9,925 Shares of Stock


© 2006-2019 Ticker Report